Skip to main content
SpringerLink
Log in

Effects of Hormonal Contraceptives on Bone Mineral Density

  • Leading Article
  • Published:
Drug Safety Aims and scope Submit manuscript

Abstract

The clinical research to date on the effects of 3 types of hormonal contraceptives, i.e. depot medroxyprogesterone acetate (‘Depo-Provera’), levonorgestrel subdermal implants (‘Norplant’), and oral contraceptives, on bone mineral density in premenopausal women is reviewed.

The large variance in results across studies for each method is in part due to differences in research design, techniques for measuring bone mineral density, age of the study participants and type of oral contraceptive preparation.

However, the balance of the evidence leans toward a positive effect of oral contraceptives on bone mineral density in women of all age. On the other hand, few observations have yet been published on the effects of the new progestin oral contraceptives on bone mineral density.

The few extant data suggest a positive impact of levonorgestrel subdermal implants on bone mineral density in women of all ages. Although the findings are preliminary, it appears that depot medroxyprogesterone acetate may exert a negative effect on bone mineral density. More specifically, caution should be exercised in prescribing long term depot medroxyprogesterone acetate (e.g. >5 years) especially in young adolescents (e.g. <16 years old) who may not have yet reached peak bone mass.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Speroff L, Glass RH, Kase NG, editors. Clinical gynecologic endocrinology and infertility. 5th ed. Baltimore (MD): William and Wilkins, 1994

    Google Scholar 

  2. Consensus Panel. Osteoporosis. JAMA 1984; 252: 799–802

    Article  Google Scholar 

  3. Delmas PD, Bjarnason NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997; 337(23): 1641–7

    Article  PubMed  CAS  Google Scholar 

  4. Recker RR, Davies M, Hinders SM. Bone gain in young adult women. JAMA 1992; 268: 2403–8

    Article  PubMed  CAS  Google Scholar 

  5. Mazess RB, Barden HS. Bone mineral density in premenopausal women: effects of age, dietary intake, physical activity, smoking, and birth control pills. Am J Clin Nutr 1991; 53: 132–42

    PubMed  CAS  Google Scholar 

  6. Kreipe DR, Forbes GB. Osteoporosis: a ‘new morbidity’ for dieting female adolescents? Pediatrics 1990; 86: 478–80

    PubMed  CAS  Google Scholar 

  7. Matkovic V, Jelic T, Wardlaw GM, et al. Timing of peak bone mass in Caucasian females and its implication for the prevention of osteoporosis: inference from a cross-sectional model. J Clin Invest 1994; 93: 799–808

    Article  PubMed  CAS  Google Scholar 

  8. Hergenroeder AC. Bone mineralization, hypothalmic amenorrhea, and sex steroid therapy in female adolescents and young adults. J Pediatr 1995; 126: 683–9

    Article  PubMed  CAS  Google Scholar 

  9. Theinz G, Buchs B, Nizzolo R, et al. Longitudinal monitoring of bone mass accumulation in healthy adolescents: evidence for a marked reduction after 16 years of age at the levels of lumbar spine and femoral neck in female subjects. J Clin Endocrinol Metab 1992; 75: 1060–5

    Article  Google Scholar 

  10. Teegarden D, Proulx WR, Martin BR, et al. Peak bone mass in young women. J Bone Miner Res 1995; 10: 711–5

    Article  PubMed  CAS  Google Scholar 

  11. Dhuper S, Warren M P, Brooks-Gunn J, et al. Effects of hormonal status on bone mineral density in adolescent girls. J Clin Endocrinol Metab 1990; 71: 1083–8

    Article  PubMed  CAS  Google Scholar 

  12. Grecu EO, Weinshelbaum A, Simmons R. Effective therapy of glucocorticoid-induced osteoporosis with medroxyprogesterone acetate. Calcif Tissue Int 1990; 46: 294–9

    Article  PubMed  CAS  Google Scholar 

  13. Cundy T, Evans M, Roberts, et al. Bone mineral density in women receiving depot medroxyprogesterone acetate for contraception. BMJ 1991; 303: 13–9

    Article  PubMed  CAS  Google Scholar 

  14. Cromer BA, McArdle Blair J, Mahan JD, et al. A prospective comparison of bone mineral density in adolescent girls on depot medroxyprogesterone acetate (Depo-Provera), levonorgestrel (Norplant), or oral contraceptives. J Pediatr 1996; 129: 671–6

    Article  PubMed  CAS  Google Scholar 

  15. Naessen T, Olson SE, Gudmundson J. Differential effects on bone mineral density of progestogen-only methods for contraception in premenopausal women. Contraception 1995; 52: 35–9

    Article  PubMed  CAS  Google Scholar 

  16. Scholes D, LaCroix AZ, Ichikawa L, et al. Depo-medroxyprogesterone acetate exposure and bone mineral density in young women. Annual Meeting of the American Society for Bone and Mineral Research: 1996 Sep 7–11; Seattle

    Google Scholar 

  17. Taneepanichskul S, Intaraprasert S, Theppisai U, et al. Bone mineral density during long-term treatment with Norplant® implants and depot medroxyprogesterone acetate: a cross-sectional study of Thai women. Contraception 1997; 56: 153–5

    Article  PubMed  CAS  Google Scholar 

  18. Taneepanichskul S, Intaraprasert S, Theppisai U, et al. Bone mineral density in long-term depot medroxyprogesterone acetate acceptors. Contraception 1997; 56: 1–3

    Article  PubMed  CAS  Google Scholar 

  19. Mandel FP, Davidson BJ, Erlik Y, et al. Effects of progestins on bone metabolism in postmenopausal women. J Reprod Med 1982; 27(8): 511–4

    PubMed  CAS  Google Scholar 

  20. Gallagher JC, Kable WT, Goldgar D. Effect of progestin therapy on cortical and trabecular bone: comparison with estrogen. Am J Med 1991; 90: 171–8

    PubMed  CAS  Google Scholar 

  21. Caird LE, Reid-Thomas V, Hannan WJ, et al. Oral progestogen-only contraception may protect against loss of bone mass in breast-feeding women. Clin Endocrinol 1994; 41: 739–45

    Article  CAS  Google Scholar 

  22. Brache V, Alvarez-Sanchez F, Faundes A, et al. Ovarian endocrine function through five years of continuous treatment with Norplant® subdermal contraceptive implants. Contraception 1990; 41(2): 169–77

    Article  PubMed  CAS  Google Scholar 

  23. Goldsmith NJ, Johnston JO. Bone mineral density: effects of oral contraceptives, pregnancy, and lactation. Am J Bone Joint Surg 1975; 57-A(5): 657–68

    Google Scholar 

  24. Shargil A. Hormone replacement therapy in perimenopausal women with a triphasic contraceptive compound: a three-year prospective study. Int J Fertil 1985: 30: 15–28

    PubMed  CAS  Google Scholar 

  25. Lindsay R, Tohme J, Kanders B. The effect of oral contraceptive use on vertebral bone mass in pre- and post-menopausal women. Contraception 1986; 34: 333–40

    Article  PubMed  CAS  Google Scholar 

  26. Hreshchyshyn MM, Hopkins A, Zylstra S, et al. Associations of parity, breast-feeding, and birth control pills with lumbar spine and femoral neck bone densities. Am J Obstet Gynecol 1988; 159: 318–22

    PubMed  CAS  Google Scholar 

  27. Lloyd T, Buchanan JR, Ursino GR, et al. Long-term oral contraceptive use does not affect trabecular bone density. Am J Obstet Gynecol 1989; 160: 402–4

    PubMed  CAS  Google Scholar 

  28. Kleerekoper M, Brienza RS, Schultz LR, et al. Oral contraceptive use may protect against low bone mass. Arch Intern Med 1991; 151: 1971–6

    Article  PubMed  CAS  Google Scholar 

  29. Rodin A, Chapman M, Ignac Fogelman. Bone density in users of combined oral contraception: preliminary reports of a pilot study. Br J Fam Plann 1991; 16: 125–9

    Google Scholar 

  30. Kritz-Silverstein D, Barrett-Connor E. Bone mineral density in post menopausal women as determined by prior oral contraceptive use. Am J Public Health 1993; 83: 100–2

    Article  PubMed  CAS  Google Scholar 

  31. Szarewski An, Hollingworth B, Guillebaud J. Depot medroxyprogesterone acetate and osteoporosis: monitor serum oestradiol concentration in users [letter]. BMJ 1994; 308: 717

    Article  PubMed  CAS  Google Scholar 

  32. Mehta S. Bone loss, contraception and lactation. Acta Obstet Gynecol Scand 1993; 72: 148–56

    Article  PubMed  CAS  Google Scholar 

  33. Cundy T, Cornish J, Evans MC, et al. Recovery of bone mineral density in women who stop using medroxyprogesterone acetate. BMJ 1993; 308: 247–8

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. College of Medicine and Children’s Hospital, Ohio State University, Columbus, Ohio, USA

    Barbara A. Cromer

Authors
  1. Barbara A. Cromer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Barbara A. Cromer.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cromer, B.A. Effects of Hormonal Contraceptives on Bone Mineral Density. Drug-Safety 20, 213–222 (1999). https://doi.org/10.2165/00002018-199920030-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-199920030-00002

Keywords

Search

Navigation